Gautam Damera1, Tuyet-Hang Pham2, Jianchun Zhang3, Christine K Ward2, Paul Newbold2, Koustubh Ranade2, Sanjay Sethi4. 1. Translational Medicine - Respiratory, Inflammation, Autoimmunity, MedImmune LLC, One Medimmune Way, Gaithersburg, MD, 20878, USA. DameraG@medimmune.com. 2. Translational Medicine - Respiratory, Inflammation, Autoimmunity, MedImmune LLC, One Medimmune Way, Gaithersburg, MD, 20878, USA. 3. Nonclinical Statistics, MedImmune LLC, One Medimmune Way, Gaithersburg, MD, 20878, USA. 4. VA WNY Healthcare System and University at Buffalo, State University of New York, Buffalo, NY, USA.
Abstract
PURPOSE: Activation of the interleukin-1β (IL-1β) signaling pathway has been implicated in COPD, but the proportion of COPD subjects whose disease is principally driven by activation of this pathway is poorly understood. In this study, we sought to differentiate an IL-1β-associated sputum signature from other inflammation-associated COPD phenotypes. METHODS: Luminex-multiplex assays were used to study IL-1β-mediated signature proteins within airway epithelium, smooth muscle, and vascular endothelial cell cultures. The IL-1β-mediated signature was tested in a longitudinal study comprising of 35 paired stable-COPD and acute exacerbation (AECOPD) sputum samples. The presence of respiratory pathogens (H. influenzae, M. catarrhalis, S. pneumoniae, and P. aeruginosa) was evaluated by sputum cultures. RESULTS: Five proteins namely TNF-α, GCSF, IL-6, CD-40L, and MIP-1β were found to be IL-1β-regulated across all donors and cell types. All five of these IL-1β-mediated proteins were significantly increased (p < 0.05) in sputum corresponding to AECOPD events showing at least a twofold increase in IL-1β (IL-1β(+) events, 18 of 35 total events), relative to preceding stable-COPD state. Sputum IL-1β levels showed no significant association (p > 0.05, spearman) with known markers of other major COPD inflammation phenotypes. In addition, there was a significant association with bacterial presence in sputum culture with an odds ratio of 9 (95 % CI 1.56, 51.9) in IL-1β(+) events versus IL-1β(-) events. CONCLUSION: Our findings provide insights into potential markers of IL-1β-associated AECOPD, and reaffirm association between IL-1β pathway activation and airway bacterial infection in COPD. Taken together, our findings could help identify COPD patient subsets who may benefit from therapies targeting IL-1β pathway.
PURPOSE: Activation of the interleukin-1β (IL-1β) signaling pathway has been implicated in COPD, but the proportion of COPD subjects whose disease is principally driven by activation of this pathway is poorly understood. In this study, we sought to differentiate an IL-1β-associated sputum signature from other inflammation-associated COPD phenotypes. METHODS: Luminex-multiplex assays were used to study IL-1β-mediated signature proteins within airway epithelium, smooth muscle, and vascular endothelial cell cultures. The IL-1β-mediated signature was tested in a longitudinal study comprising of 35 paired stable-COPD and acute exacerbation (AECOPD) sputum samples. The presence of respiratory pathogens (H. influenzae, M. catarrhalis, S. pneumoniae, and P. aeruginosa) was evaluated by sputum cultures. RESULTS: Five proteins namely TNF-α, GCSF, IL-6, CD-40L, and MIP-1β were found to be IL-1β-regulated across all donors and cell types. All five of these IL-1β-mediated proteins were significantly increased (p < 0.05) in sputum corresponding to AECOPD events showing at least a twofold increase in IL-1β (IL-1β(+) events, 18 of 35 total events), relative to preceding stable-COPD state. Sputum IL-1β levels showed no significant association (p > 0.05, spearman) with known markers of other major COPD inflammation phenotypes. In addition, there was a significant association with bacterial presence in sputum culture with an odds ratio of 9 (95 % CI 1.56, 51.9) in IL-1β(+) events versus IL-1β(-) events. CONCLUSION: Our findings provide insights into potential markers of IL-1β-associated AECOPD, and reaffirm association between IL-1β pathway activation and airway bacterial infection in COPD. Taken together, our findings could help identify COPDpatient subsets who may benefit from therapies targeting IL-1β pathway.
Authors: Richard E K Russell; Sarah V Culpitt; Carmen DeMatos; Louise Donnelly; Michael Smith; John Wiggins; Peter J Barnes Journal: Am J Respir Cell Mol Biol Date: 2002-05 Impact factor: 6.914
Authors: Timothy F Murphy; Aimee L Brauer; Andrew T Schiffmacher; Sanjay Sethi Journal: Am J Respir Crit Care Med Date: 2004-04-29 Impact factor: 21.405
Authors: Michelle L Hernandez; Katherine Mills; Martha Almond; Krista Todoric; Maria M Aleman; Hongtao Zhang; Haibo Zhou; David B Peden Journal: J Allergy Clin Immunol Date: 2014-09-05 Impact factor: 10.793
Authors: Sukhwinder Singh Sohal; Amir Soltani; David Reid; Chris Ward; Karen E Wills; H Konrad Muller; Eugene Haydn Walters Journal: Int J Chron Obstruct Pulmon Dis Date: 2014-05-27
Authors: Joshua B Lewis; Jared S Bodine; Jason R Gassman; Samuel Arce Muñoz; Dallin C Milner; Todd M Dunaway; Kaleb M Egbert; Troy D Monson; Dallin S Broberg; Juan A Arroyo; Paul R Reynolds Journal: Environ Sci Pollut Res Int Date: 2018-04-25 Impact factor: 4.223
Authors: Stefanie Krick; Alexander Grabner; Nathalie Baumlin; Christopher Yanucil; Scott Helton; Astrid Grosche; Juliette Sailland; Patrick Geraghty; Liliana Viera; Derek W Russell; J Michael Wells; Xin Xu; Amit Gaggar; Jarrod Barnes; Gwendalyn D King; Michael Campos; Christian Faul; Matthias Salathe Journal: Eur Respir J Date: 2018-07-04 Impact factor: 16.671
Authors: Arindam Chakrabarti; Jordan S Mar; David F Choy; Yi Cao; Nisha Rathore; Xiaoying Yang; Gaik W Tew; Olga Li; Prescott G Woodruff; Christopher E Brightling; Michele Grimbaldeston; Stephanie A Christenson; Mona Bafadhel; Carrie M Rosenberger Journal: ERJ Open Res Date: 2021-08-02